Nykode Therapeutics Investor Relations Material

Nykode Therapeutics AS is a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies in the fields of cancer and infectious diseases. The company develops vaccines for the treatment cancer, melanoma, lung, head and neck, renal, bladder cancer; Nkyode Therapeutics AS was formerly known as Vaccibody AS. The Company's lead product candidates include VB10.NEO (Oncolytic Immunotherapy), which has completed Phase I/IIa clinical trial; it also has development collaboration agreements with Roche, Genentech and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; research agreement with Regeneron.